# OPCH Q3 2025 - åŸ·è¡Œæ‘˜è¦

**æ›´æ–°æ—¥æœŸ**: 2025-11-18  
**ç•¶å‰è‚¡åƒ¹**: $28.28 (2025-11-18)  
**è²¡å ±å¾Œè‚¡åƒ¹**: $26.21 (2025-10-30, -8.6%)  
**åˆ†æå®Œæˆåº¦**: 100% âœ…

---

## ğŸ¯ ä¸€å¥è©±ç¸½çµ

**é›™ä½æ•¸ç‡Ÿæ”¶èˆ‡èª¿æ•´å¾Œ EPS æ‰“æ•—å¸‚å ´ï¼Œä½†æ¯›åˆ©ç‡è¢« Stelara biosimilar èˆ‡ç¨€æœ‰ç™‚æ³• mix å£“ç¸®ï¼ŒçŸ­ç·šè©•åƒ¹å—é™ï¼Œç­‰å¾…æ¯›åˆ©ä¼ç©©èˆ‡é€²éšè¨ºæ‰€é‡ç”¢ã€‚**

---

## ğŸ“Š æŠ•è³‡è©•ç´š

### â­â­â­â˜†â˜† - **HOLD**

| æŒ‡æ¨™ | æ•¸å€¼ |
|------|------|
| **ç•¶å‰è‚¡åƒ¹** | $28.28 |
| **ç›®æ¨™åƒ¹å€é–“** | **$25 - $31** |
| **ä¸­ä½æ•¸ç›®æ¨™åƒ¹** | **$28** |
| **æ½›åœ¨å›å ±** | **0%** (è‡³ä¸­ä½) |
| **è‚¡æ¯æ”¶ç›Šç‡** | **0.0%** (ç„¡é…æ¯) |
| **ç¸½å›å ±é æœŸ** | **0%** |
| **å»ºè­°è²·å…¥åƒ¹ä½** | **$24 - $26** |
| **é¢¨éšªå›å ±æ¯”** | **1:1** |

> ä¼°å€¼ 16.6x 2025E Adj. EPS / 11.4x EV/EBITDA å·²æ¥è¿‘åˆç†åƒ¹ï¼Œæ¯›åˆ©æŒçºŒæ‰¿å£“ä½¿ä¸Šæª”ç©ºé–“æœ‰é™ã€‚ç­‰å¾… $24-$26 å†è€ƒæ…®å»ºå€‰ã€‚

---

## ğŸ”‘ ä¸‰å¤§æ ¸å¿ƒæ´å¯Ÿ

### 1ï¸âƒ£ æˆé•·æ¼‚äº®ä½†ç›ˆåˆ©å“è³ªè¢«è³ªç–‘
- **å¸‚å ´åæ‡‰**: EPS $0.45 beat +$0.02ï¼Œè‚¡åƒ¹ä»åœ¨è²¡å ±æ—¥è·Œ 8.6%ã€‚
- **ä¸»è¦é©…å‹•**: æ¯›åˆ©ç‡ 19.0% (-110 bps) å›  Stelara biosim adoption é€ æˆ 380 bps revenue drag ä¸” rare/orphan ç™‚æ³•å æ¯”æå‡ã€‚
- **ç®¡ç†å±¤å¼•è¿°**: > "Gross margin rate was negatively impacted by the shifting Stelara dynamics as well as the impact from lower margin, limited distribution, and rare and orphan therapies." â€” CFO Meenal Sethna
- **çµè«–**: æ¯›åˆ©å£“åŠ›æ‰æ˜¯å¸‚å ´ç„¦é»ï¼ŒEPS beat ä¸»è¦é å›è³¼èˆ‡ç¨…ç‡ã€‚

### 2ï¸âƒ£ è³‡æœ¬é…ç½®èˆ‡æµå‹•æ€§æä¾›ä¸‹æª”ä¿è­·
- YTD CFFO $222.6Mï¼Œè¶³ä»¥æ”¯æ’ $117M Intramed Plus äº¤æ˜“ã€$27.7M capex èˆ‡ $212.5M å›è³¼ã€‚
- 9/22 é‡æ–°è­°ç´„ First Lien Term Loanï¼Œåˆ©ç‡é™è‡³ SOFR+175 bps ä¸¦å»¶é•·è‡³ 2032 å¹´ï¼Œæ·¨æ§“æ¡¿ 1.9xï¼ŒRevolver å¯å‹•ç”¨ $396Mã€‚
- **çµè«–**: ç¾é‡‘æµèˆ‡é™æˆæœ¬è² å‚µçµæ§‹è®“å…¬å¸èƒ½åœ¨æ¯›åˆ©æ‰¿å£“æ™‚ä»ç¶­æŒç©æ¥µæŠ•è³‡ã€‚

### 3ï¸âƒ£ é€²éšè¨ºæ‰€èˆ‡è‡ªå‹•åŒ–æ˜¯ä¸­æœŸä¿®å¾©æ¯›åˆ©é—œéµ
- NavenHealth Q3 å®Œæˆ 55k æŠ¤ç†æœå‹™ï¼Œ175 å€‹æ“šé»ä¸­ 24 å€‹ advanced practitioner site å¯æœå‹™è¼ƒé«˜è¤‡é›œåº¦ç—…æ‚£ã€‚
- CFO: > "We launched three new enhanced applications that we expect to drive efficiencies in our patient onboarding process... staffing, utilization, and deliveries."
- **çµè«–**: æ“´å¼µé€²éšè¨ºæ‰€ï¼‹AI è‡ªå‹•åŒ–æœ‰æœ›æå‡ mix èˆ‡ SG&A æ•ˆç‡ï¼Œä½†éœ€ 6-12 å€‹æœˆæ‰èƒ½åæ˜ åœ¨è²¡å ±ã€‚

---

## ğŸš€ æ–°æ©Ÿæœƒèˆ‡å‚¬åŒ–åŠ‘

### ğŸ†• Advanced Practitioner Network Scaling
- **å•é¡Œè¨ºæ–·**: é«˜è¤‡é›œåº¦ç™‚æ³•éœ€è¦è‡¨åºŠç›£ç£ï¼Œå®¶åº­è¼¸æ³¨æ¨¡å¼ä¸è¶³ã€‚
- **è§£æ±ºæ–¹æ¡ˆ**: æ•´åˆ Intramed Plus æœ€ä½³å¯¦å‹™ã€æ“´å¤§ 24 å€‹ advanced practitioner site è¦†è“‹ï¼Œçµåˆè‡ªæœ‰è—¥å±€èˆ‡ NavenHealth è­·ç†åœ˜éšŠã€‚
- **æ™‚ç¨‹èˆ‡å½±éŸ¿**: 2025-2026 æŒçºŒ rolloutï¼Œå¯æå‡é«˜æ¯›åˆ©ç™‚æ³•æ»²é€ã€‚
- **ç®¡ç†å±¤å¼•è¿°**: > "Weâ€™re going to continue to look to expand... it expands access to a broader set of patients." â€” CEO John Rademacher

### ğŸ†• Automation & AI å¹³å°
- **å•é¡Œè¨ºæ–·**: Onboardingã€æ´¾å·¥ã€ç‰©æµæµç¨‹äººå·¥å¯†é›†ã€‚
- **è§£æ±ºæ–¹æ¡ˆ**: èˆ‡ Palantirã€RPAã€ML åˆä½œï¼Œä¸Šç·š 3 å€‹æ–°æ‡‰ç”¨ä»¥å„ªåŒ–ç—…æ‚£ç”„æ ¸ã€æ’ç­èˆ‡é…é€ã€‚
- **æ™‚ç¨‹èˆ‡å½±éŸ¿**: Q3 å·²ä¸Šç·šï¼Œé è¨ˆ 2026 å¹´å‰é€æ­¥é™ä½ DSOï¼ˆ30.1 å¤©ï¼‰ä¸¦å£“ä½ SG&Aã€‚

### ğŸ†• è³‡æœ¬é…ç½®å½ˆæ€§
- **å•é¡Œè¨ºæ–·**: éœ€è¦åœ¨ä½µè³¼ã€å…§éƒ¨æŠ•è³‡èˆ‡å›è³¼é–“å–å¾—å¹³è¡¡ã€‚
- **è§£æ±ºæ–¹æ¡ˆ**: Term Loan é™æ¯ + Revolver $396Mï¼Œå„ªå…ˆæŠ•è³‡è¨ºæ‰€ã€IT èˆ‡é«˜ ROI å°ˆæ¡ˆï¼Œå†è€ƒæ…®è¿‘é„°ä½µè³¼èˆ‡ $287.5M å‰©é¤˜å›è³¼æˆæ¬Šã€‚
- **æ™‚ç¨‹èˆ‡å½±éŸ¿**: 2025-2026 æ¯å¹´ç¶­æŒ >$200M å›è³¼èˆ‡ç­–ç•¥ä½µè³¼å½ˆæ€§ï¼Œæ”¯æ’èª¿æ•´å¾Œ EPS CAGRã€‚

---

## ğŸ“ˆ é—œéµè²¡å‹™æ•¸æ“š

### Q3 2025 è¡¨ç¾

| æŒ‡æ¨™ | æœ¬å­£ | å»å¹´åŒæœŸ | YoY | è©•ä¼° |
|------|------|---------|-----|------|
| **ç¸½ç‡Ÿæ”¶** | $1,435M | $1,279M | +12.2% | âœ… ç«¶å“ä¾›æ‡‰åƒç·Šï¼‹ç™‚æ³•çµ„åˆæ“´å¤§ |
| Commercial payers | $1,252M | $1,110M | +12.8% | âœ… å¸æ”¶è½‰å–®ã€æ€¥æ€§ mid-teens |
| Government payers | $173M | $147M | +17.5% | âœ… Medicare/Medicaid æ»²é€ |
| **ç‡Ÿæ¥­åˆ©æ½¤** | $84.5M | $85.1M | -0.7% | âš ï¸ æ¯›åˆ©ç‡ä¸‹æ»‘ |
| **ç‡Ÿæ¥­åˆ©æ½¤ç‡** | 5.9% | 6.7% | -80 bps | âš ï¸ Stelara/rare therapies mix |
| **èª¿æ•´å¾Œ EBITDA** | $119.5M | $115.6M | +3.4% | âš ï¸ margin 8.3% (-70 bps) |
| **èª¿æ•´å¾Œ EPS** | $0.45 | $0.41 | +9.8% | âœ… å›è³¼ï¼‹ç¨…ç‡é™ |
| **CFFO (YTD)** | $222.6M | $287.3M | -22.5% | âš ï¸ AR/åº«å­˜ä½”ç”¨ |

### åˆ†éƒ¨åˆ©æ½¤ç‡ï¼ˆé—œéµæŒ‡æ¨™ï¼‰

| åˆ†éƒ¨ | æœ¬å­£ | å»å¹´ | è®ŠåŒ– | è©•ä¼° |
|------|------|------|------|------|
| Acute therapies | mid-teens growth | low-teens | +200 bps mix | âœ… volume é«˜ä½†æ¯›åˆ©ä½æ–¼å¹³å‡ |
| Chronic therapies | low double-digit growth | high single-digit | +300 bps | âš ï¸ Stelara conversion -380 bps revenue |
| Rare & orphan / limited distribution | é«˜å€‹ä½æ•¸æˆé•· | é«˜å€‹ä½æ•¸ | æŒå¹³ | âš ï¸ ä½æ¯›åˆ©æ‹–ç´¯ç¸½é«” GM |

---

## ğŸ“Œ å¾ŒçºŒé‡é»

- ğŸ” **ç›£æ§æŒ‡æ¨™**: æ¯›åˆ©ç‡è»Œè·¡ã€Stelara biosim æ»²é€ã€DSOã€SG&A/Revenueã€Net interest run-rate (~$55-57M)ã€‚
- ğŸ“… **ä¸‹ä¸€å€‹å‚¬åŒ–åŠ‘**: 2025/02 Q4 è²¡å ± + 2026 å±•æœ›ã€é€²éšè¨ºæ‰€ rollout æ›´æ–°ã€æ½›åœ¨è¿‘é„°ä½µè³¼å…¬å‘Šã€‚
- ğŸ§­ **æŠ•è³‡æ™‚é–“ç·š**: 6-12 å€‹æœˆç­‰å¾…æ¯›åˆ©ä¼ç©©ï¼›12-18 å€‹æœˆè§€å¯Ÿ advanced practitioner èˆ‡è‡ªå‹•åŒ–æˆæœã€‚
